MedTrace Logo

MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy

NCT05471128 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2026-02-10

No results posted yet for this study

Summary

The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).

Conditions

Interventions

PROCEDURE

Standard of Care Biopsy

Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Andrew McIntosh, MD · University of Oklahoma Stephenson Cancer Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-27
Primary Completion
2025-05-01
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05471128 on ClinicalTrials.gov